Clinical trials: Advanced Solid Malignancy
Solid Tumor
Dose Escalation Trial of BNT152+153 in Patients With Cancer
This is an open-label, multisite Phase I dose escalation, safety, pharmacokinetics (PK) and pharmacodynamics (PD) trial of BNT152+153 in various solid tumor indications.
- Trial name
- NCT04710043
- Testing
- BNT152, BNT153
- Where
- 7 sites in United States, Czechia
- Volunteers
- 86 people
- Sponsor
- BioNTech SE
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma
A Phase I Study of JLM019 Injection
This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies.
- Conditions
- Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- JLM019 (NCT07623850)
- Testing
- JLM019 Injection
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors, Metastatic Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizumab in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT05487235
- Testing
- GDC-1971, Atezolizumab, Omeprazole
- Where
- 25 sites in Argentina, Australia and 4 more
- Volunteers
- 57 people
- Sponsor
- Genentech, Inc.
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080，or letrozole and trastuzumab, with or without pertuzumab…
- Trial name
- NCT06555068
- Testing
- HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumors
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.
- Trial name
- NCT04237649
- Testing
- KAZ954, PDR001, NIR178
- Where
- 13 sites in United States, Canada and 6 more
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Advanced Solid Tumor
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
- Trial name
- NCT06952010
- Testing
- XB628, Zanzalintinib
- Where
- 11 sites in United States
- Volunteers
- 303 people
- Sponsor
- Exelixis
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumor
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose…
- Trial name
- NCT05381935
- Testing
- ES014
- Sponsor
- Elpiscience Biopharma, Ltd.
Advanced Solid Tumor
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in…
- Trial name
- NCT06132217
- Testing
- Simmitinib, SG001
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Neoplasms
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of [177Lu]-NeoB in patients with advanced solid tumors known to overexpress…
- Trial name
- NeoRay (NCT03872778)
- Testing
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 35 people
- Sponsor
- Advanced Accelerator Applications
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
- Trial name
- NCT03098550
- Testing
- Nivolumab, Daratumumab
- Where
- 20 sites in United States, Australia and 7 more
- Volunteers
- 105 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Metastatic Bladder Cancer
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).
- Trial name
- NCT02030067
- Testing
- RX-3117
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Processa Pharmaceuticals
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied.
- Trial name
- EPI VITRAKVI (NCT05236257)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556), Standard of Care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Bayer
Advanced Solid Tumors
Study of CM529D1 in Participants With Advanced Solid Tumors
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
- Trial name
- NCT07893171
- Testing
- CM529D1
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumor
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined…
- Trial name
- NCT05794477
- Testing
- Adebrelimab, SHR-1802, Carboplatin/Cisplatin
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.